#1 Clinical Trials Search in Europe

Mercaptamine

Mercaptamine, also known as cysteamine bitartrate, is a drug that has shown promise in treating rare genetic disorders such as cystinosis and inherited mitochondrial diseases. This article explores recent clinical trials investigating the effectiveness, safety, and potential benefits of mercaptamine in various formulations, including delayed-release capsules. We’ll examine how this medication works to reduce harmful substances in the body and its potential to improve the quality of life for patients with these challenging conditions.

Table of Contents

What is Mercaptamine?

Mercaptamine, also known as cysteamine bitartrate, is a medication used to treat a rare genetic disorder called cystinosis[1]. This drug is available under various brand names, including Cystagon® and Procysbi® (RP103)[5]. Mercaptamine is designed to help reduce the buildup of a substance called cystine in the body, which is the primary issue in cystinosis[3].

What Conditions Does Mercaptamine Treat?

Mercaptamine is primarily used to treat cystinosis, a rare inherited disease that affects various organs in the body, particularly the kidneys[3]. If left untreated, cystinosis can lead to kidney failure as early as the first decade of life[4]. In addition to cystinosis, some studies have explored the potential use of mercaptamine in treating other conditions:

  • Inherited mitochondrial diseases: These are a group of genetic disorders that affect the mitochondria, which are the energy-producing structures in cells[2].
  • Nonalcoholic fatty liver disease (NAFLD) in children: This is a condition where excess fat accumulates in the liver of people who drink little or no alcohol[6].

How Does Mercaptamine Work?

In cystinosis, the body accumulates an amino acid called cystine in various cells and organs. Mercaptamine works by helping to reduce the levels of cystine in the body[3]. It does this by entering cells and reacting with cystine, forming compounds that can exit the cells more easily. This process helps prevent the harmful buildup of cystine and reduces damage to organs, especially the kidneys[4].

How is Mercaptamine Administered?

Mercaptamine is typically taken orally in the form of capsules. The dosage and frequency of administration can vary depending on the specific formulation and the patient’s needs:

  • Cystagon®: This formulation is usually taken every six hours[4].
  • Procysbi® (RP103): This is a delayed-release formulation that is typically taken every 12 hours[5]. It’s designed to be absorbed from the small intestine rather than the stomach, which may allow for less frequent dosing[3].

For young children or those unable to swallow capsules, the medication can sometimes be administered via a gastrostomy tube (G-tube)[3].

Clinical Studies on Mercaptamine

Several clinical trials have been conducted to evaluate the safety and effectiveness of mercaptamine:

  • Pediatric studies: Research has been done to assess the use of mercaptamine in children as young as 6 months old with cystinosis[1].
  • Comparison studies: Trials have compared the effectiveness of different formulations, such as Cystagon® versus Procysbi® (RP103)[5].
  • Long-term studies: Some trials have followed patients for extended periods to assess the long-term safety and effectiveness of mercaptamine[3].
  • Studies in other conditions: Research has explored the potential use of mercaptamine in conditions like inherited mitochondrial diseases and nonalcoholic fatty liver disease in children[2][6].

Potential Side Effects

Like all medications, mercaptamine can cause side effects. Some of the reported side effects include:

  • Gastrointestinal issues: Nausea, vomiting, and stomach discomfort are common[5].
  • Halitosis: Some patients experience bad breath (halitosis) when taking mercaptamine[5].
  • Other side effects: These may include headaches, tiredness, and skin rashes[5].

It’s important to discuss any side effects with your healthcare provider, as they can often be managed through dose adjustments or other strategies.

Special Considerations

There are several important points to keep in mind when taking mercaptamine:

  • Regular monitoring: Patients taking mercaptamine typically need regular blood tests to monitor the levels of cystine in their white blood cells. This helps ensure the medication is working effectively[3].
  • Lifelong treatment: For patients with cystinosis, mercaptamine treatment is typically needed for life to prevent complications of the disease[4].
  • Food effects: The absorption of mercaptamine can be affected by food. Some studies have investigated how different types of meals might impact the drug’s effectiveness[7].
  • Pregnancy and breastfeeding: If you’re pregnant, planning to become pregnant, or breastfeeding, it’s crucial to discuss the use of mercaptamine with your healthcare provider.

Remember, mercaptamine is a powerful medication that requires careful management under the guidance of a healthcare professional. Always follow your doctor’s instructions and report any concerns or side effects promptly.

Aspect Details
Drug Name Mercaptamine (Cysteamine Bitartrate)
Formulations Delayed-release capsules (RP103, Procysbi), immediate-release capsules (Cystagon)
Main Conditions Studied Cystinosis, Inherited Mitochondrial Diseases
Key Outcome Measures White blood cell cystine levels, Newcastle Paediatric Mitochondrial Disease Scale, safety and tolerability
Dosing Frequency Typically twice daily for delayed-release formulations, compared to four times daily for older formulations
Notable Side Effects Halitosis (bad breath) reported in some patients
Potential Benefits Reduced cystine accumulation, improved quality of life, potential for less frequent dosing
Trial Durations Ranging from several months to over a year, with some long-term extension studies

FAQ

  • What is mercaptamine and what conditions does it treat? Mercaptamine, also known as cysteamine bitartrate, is a medication used to treat rare genetic disorders such as cystinosis and inherited mitochondrial diseases. It works by reducing the buildup of certain harmful substances in the body's cells.
  • How is mercaptamine administered in clinical trials? In clinical trials, mercaptamine is often administered as delayed-release capsules (RP103 or Procysbi) taken orally or via gastrostomy tube. The dosage and frequency vary depending on the study, but it's typically given twice daily instead of four times a day like older formulations.
  • What are the main outcomes measured in mercaptamine clinical trials? Clinical trials for mercaptamine typically measure outcomes such as changes in white blood cell cystine levels, improvements in disease-specific scales (e.g., Newcastle Paediatric Mitochondrial Disease Scale), safety and tolerability, and quality of life measures.
  • Are there any side effects associated with mercaptamine in clinical trials? While specific side effects can vary, some patients in clinical trials have reported experiencing halitosis (bad breath) with certain formulations of mercaptamine. Researchers are investigating this and other potential side effects to improve patient comfort and treatment adherence.
  • How long do mercaptamine clinical trials typically last? The duration of mercaptamine clinical trials can vary, but many studies last several months to over a year. Some trials include long-term extension phases to gather data on the medication's effectiveness and safety over extended periods.

Ongoing Clinical Trials on Mercaptamine

  • Study of cysteamine combined with standard tuberculosis treatment in adults with pulmonary tuberculosis

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Safety of Mercaptamine with Standard Therapy for Hospitalized COVID-19 Pneumonia Patients Not Requiring High Oxygen Flows

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Cystinosis: A rare genetic disorder characterized by an accumulation of the amino acid cystine in various organs and tissues, leading to damage, especially in the kidneys and eyes.
  • Mitochondrial disease: A group of disorders caused by dysfunctional mitochondria, the energy-producing structures in cells. These diseases can affect multiple organ systems and often impact energy-intensive tissues like the brain, muscles, and heart.
  • Cysteamine bitartrate: The active ingredient in mercaptamine medications, which helps reduce the buildup of cystine in cells of patients with cystinosis.
  • Delayed-release capsules: A formulation of medication designed to release the active ingredient in the small intestine rather than the stomach, potentially allowing for less frequent dosing and improved effectiveness.
  • White blood cell (WBC) cystine level: A laboratory test used to measure the amount of cystine in white blood cells, which helps determine the effectiveness of cysteamine treatment in patients with cystinosis.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and biochemical and physiological effects.
  • Newcastle Paediatric Mitochondrial Disease Scale (NPMDS): A clinical assessment tool used to evaluate the progression and severity of mitochondrial disease in pediatric patients across multiple domains.
  • Halitosis: Medical term for bad breath, which has been reported as a side effect in some patients taking certain formulations of cysteamine bitartrate.
  • Glutathione: An important antioxidant in the body that helps protect cells from damage and is sometimes measured as a biomarker in clinical trials of cysteamine bitartrate.

References

  1. https://clinicaltrials.gov/study/NCT04125927
  2. https://clinicaltrials.gov/study/NCT02473445
  3. https://clinicaltrials.gov/study/NCT01744782
  4. https://clinicaltrials.gov/study/NCT00872729
  5. https://clinicaltrials.gov/study/NCT01733316
  6. https://clinicaltrials.gov/study/NCT01529268
  7. https://clinicaltrials.gov/study/NCT01432561